Brief: Anpac Bio’S Investee Company In China Receives Covid-19 Nucleic Acid Test Certification
02/11/2020 12:32
Nov 2 (Reuters) - AnPac Bio-Medical Science Co Ltd ANPC.O :
* ANPAC BIO’S INVESTEE COMPANY IN CHINA RECEIVED COVID-19
NUCLEIC
ACID TEST CERTIFICATION AND BEGAN VOLUME TESTS AND
COLLABORATIONS WITH ANPAC BIO
Source text for Eikon: ID:nGNX247qxq
Further company coverage: ANPC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fresh2
See all newsBrief: Fresh2 Group On Dec 20, Received Nasdaq Notice That It Will Be Delisted From Nasdaq Capital Market Effective At Open Of Market On Dec 24
Brief: Fresh2 Group Ltd. Announces Receipt Of Staff Delisting Determination From Nasdaq Intends To Request A Hearing
Brief: Fresh2 Group Ltd Announces Receipt Of A Delinquency Compliance Alert Notice From Nasdaq
Brief: Anpac Bio-Medical Science - In Dec 2022 And Jan 2023, Signed Definitive Investment Agreements With Several Third Party Investors
Brief: AnPac Bio Granted Continued Listing By Nasdaq Hearing Panel, Subject To Meeting $1 Bid Price Compliance Rule On Or Before Nov. 23, 2022